Acquisition Definition Pricing San Diego 
socalTECH
MAY 20, 2013
San Diego-based security software developer Websense announced this morning that it has signed a definitive agreement to be acquired by private equity firm Vista Equity Partners. Websense said the deal is an approximate premium of 29 percent over the firm''s Friday closing price. per share in cash for the company.
socalTECH
DECEMBER 22, 2017
San Diego-based precision medicine developer Ignyta has agreed to be acquired by biopharmaceuticals giant Roche , in a $1.7 According to the two, they are in a definitive merger agreement, where Roche will acquire Ignyta for $27.00 The companies said the price is a premium of 74% on Ignyta's closing price on Thursday.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
socalTECH
OCTOBER 7, 2009
San Diego-based Gen-Probe said Tuesday that it has signed a definitive agreement to acquire Prodesse, a provider of molecular testing for influenza and other infection diseases. The deal is worth $60M in cash, with provision to increase the price to $85M on meeting specific financial and regulatory milestones.
socalTECH
JANUARY 24, 2011
San Diego-based Genoptix , a publicly held provider of laboratory services to the hematology and oncology market, said this morning that it is in a definitive merger agreement to be acquired by Novartis. Genoptix said the offer is a 27 percent premium over its closing price of $19.76
socalTECH
OCTOBER 17, 2011
San Diego-based Anadys Pharmaceuticals , the developer of treatments for hepatitis C, said this morning that it has agreed to be acquired by Roche. The firm said it signed a definitive merger agreement where Roche will pay $3.70 The price is a 256 percent premium over the $1.04
Xconomy
JUNE 28, 2016
If buyers and sellers don’t have a meeting of the minds early on in the game, it’s possible that, deeper into negotiations, the proposed terms in the definitive agreement could derail weeks of work, wasting everyone’s time and energy. ESCROW: The parties typically agree to set aside 10 percent of the purchase price in an escrow account.
Xconomy
AUGUST 12, 2016
—Option-to-buy deals are by definition no guarantee, and an agreement between Boston-based Acetylon Pharmaceuticals and Celgene is the latest example. Celgene paid Acetylon $100 million in 2013 for an option to buy the company outright, but the deal recently expired without an acquisition, leaving Acetylon to chart a new course.
Expert insights. Personalized for you.
159 
Let's personalize your content